233 results about "Membrane vesicle" patented technology

The invention relates to a curcumin-loaded MMP response type melittin nano-pellicle vesicle as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing curcumin entrapped lipidosome; then carrying out culture amplification on engineering bacteria carrying melittin recombinant plasmids, extracting cell membranes after removing cell walls, and carrying out ultrasonic treatment and membrane extrusion to obtain melittin cell membrane nano-vesicles; fusing the curcumin lipidosome and the cell membrane nano-vesicles in an ultrasonic extrusion mode to obtain fused vesicles; and finally, carrying out surface calcium phosphate mineralization treatment on the fused vesicles to obtain the curcumin-loaded MMP response type melittin nano pellicle vesicles. The nano mycofilm vesicle prepared by the invention can be used for preparing antitumor drugs, and the biocompatibility and in-vivo stability of nanoparticles are improved by introducing a calcium phosphate coating; through combined delivery of melittin and curcumin, the anti-tumor effect is enhanced, so that the growth and proliferation of tumor cells are inhibited.

Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and / or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.

The present invention relates to the technical field of diabetes, and in particular to a controlled-release diabetic wound healing promoting treatment method, comprising the following treatment experimental steps: step S1: preparation of Hst1@PNPs; step S2: Coomassie brilliant blue staining; step S3: scanning and transmission electron microscopy detection; in the present invention, a slow-release Hst1 treatment method is constructed by encapsulating Hst1 into platelet membrane vesicles derived from autologous blood. On the one hand, the PNPs encapsulate the linear Hst1 peptide structure to prevent it from being rapidly degraded by high proteases in diabetic wound exudate, thereby improving bioavailability. On the other hand, the PNPs can adsorb excess LPS in the wound exudate, and cooperate with Hst1 to achieve anti-inflammatory and anti-oxidative stress effects. Subsequent cell and animal experiments further confirmed that Hst1@PNPs have the effects of anti-inflammatory, scavenging ROS, promoting re-epithelialization, collagen deposition and angiogenesis, thereby promoting diabetic wound healing.

The invention belongs to the technical field of biological medicine, and discloses a bionic nano-particle suspension formulation based on orthoester compounds and a preparation method of the bionic nano-particle suspension formulation. The bionic nanoparticle suspension formulation comprises a liquid auxiliary material, a photosensitizer and bionic nanoparticles, wherein the photosensitizer and the bionic nanoparticles are dispersed in the liquid auxiliary material. According to the present invention, an orthoester compound represented by a formula I is adopted as a liquid auxiliary material, bionic nanoparticles and a photosensitizer are simultaneously introduced into OE to obtain the bionic nanoparticle suspension formulation having multiple antitumor mechanisms, the bionic nanoparticles are cancer cell membrane vesicle-coated nano-drugs, and the cancer cell membrane vesicle-coated nano-drugs can be prepared through a cancer cell membrane biomimetic technology, such that the cancer cell membrane vesicle-coated nano-drugs can be prepared into the bionic nanoparticle suspension formulation having multiple antitumor mechanisms; the homologous targeting function provided by the cancer cell membrane is utilized, and the active targeting property and cellular uptake of the nano-drug are remarkably improved. Formula I: # imgabs0 #

The present invention relates to Shigella outer membrane vesicles comprising at least one heterologous O-antigen, a recombinant Shigella bacterium comprising at least one heterologous O-antigen, methods for preparing the outer membrane vesicles or recombinant Shigella bacterium, plasmids for use in the methods, immunogenic compositions, vaccines and methods of treatment.

The invention provides magnesium manganese carbonate nanoparticles wrapped by cell membrane vesicles as well as a preparation method and application of the magnesium manganese carbonate nanoparticles. The nanoparticles comprise tumor cell-derived membrane vesicles highly expressing PD1; the MgMn nano-particle compound is wrapped in the vesicles; the magnesium manganese carbonate nano-particles (CVs (at) MgMn) wrapped by the cell membrane vesicles provided by the invention integrate numerous advantages of Mg < 2 + > and Mn < 2 + > ions, not only have immune regulation and control and tumor killing effects, but also can realize radiotherapy sensitization, have immune regulation and control and microenvironment remodeling effects on any type of solid tumors, and can be used for preparing a medicine for treating tumor tumors. And the nano-particles are universal multifunctional composite nano-particles.

The invention belongs to the field of medicine, and discloses application of POCM-NP-coated A939572 in preparation of a medicine for treating osteoporosis, the POCM-NP-coated A939572 comprises osteoclast precursor cell membrane vesicles and NP-coated A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP-coated A939572 is PLGA (poly (lactic-co-glycolic acid)) nanoparticles entrapped with the NP-coated A939572. The POCM-NP-coated A939572 obtained by loading the nanoparticles loaded with the A939572 small molecule medicine into the osteoclast precursor cell membrane vesicles has the effect of relieving the osteoporosis, can inhibit osteoclast differentiation and can be used for preventing, treating and relieving the osteoporosis.

The invention relates to application of visceral odorobacter and outer membrane vesicles thereof in preparation of drugs for treating acute lung injury, and relates to the technical field of drugs. The modeling medicine lipopolysaccharide is applied to a mouse individual in a nasal dripping mode, the administration mode is that each mouse is administered once a day, and intragastric administration is carried out once a day after modeling is carried out for two days and lasts for 7 days. Experiments prove that visceral odorobacter and outer membrane vesicles of the visceral odorobacter reduce the number of M1 type alveolar macrophages by down-regulating proinflammatory factors IL-6, TNF-alpha and IL-1beta in lung tissues and inhibiting three proinflammatory factors IL-6, TNF-alpha and IL-1beta in serum, so that the effect of remarkably reversing acute lung injury is achieved. The visceral odor bacilli and the outer membrane vesicles thereof are used for preventing and treating the acute lung injury, and a new method and means are provided for clinically treating the acute lung injury.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

The invention belongs to the technical field of biology, and relates to an immunocompetence composition and a pertussis vaccine containing the immunocompetence composition. The immunocompetence composition comprises pertussis Bordetella outer membrane vesicles and attenuated pertussis toxins in a weight ratio of (5-50): (5-25). Effective protective immunity can be triggered in the process of preventing pertussis infection, pertussis bacteria in the lung are effectively eradicated, and bacterial colonization in the trachea and the nasal cavity is remarkably reduced.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

Provided herein is a hypervesiculating Escherichia coli Nissle (ΔECHy) bacterium engineered to produce outer membrane vesicles (OMVs), said OMVs packaging a fusion peptide including cytolysin A (ClyA) and hyaluronidase (Hy). Also provided are methods of remodeling a tumor, methods of treating cancer, and pharmaceutical compositions including the engineered ΔECHy bacterium.

The present invention belongs to the field of microbiology, and particularly relates to membrane vesicles (MVs) isolated from bacteria, and an isolation and preparation system and method for the membrane vesicles, and applications of the membrane vesicles. The bacteria of the present invention comprise Gram-positive bacteria and Gram-negative bacteria. The invention uses ionizing irradiation to irradiate bacteria, and isolates and purifies the produced membrane vesicles. The membrane vesicles prepared can be used as a vaccine, a vaccine adjuvant and / or a pharmaceutical carrier. In addition, the present invention provides a biological composition comprising the membrane vesicles and inactivated bacteria. In addition, the present invention also provides a preparation system, and isolation and purification system for bacterial membrane vesicles and the corresponding method. The membrane vesicles obtained by using the system and method have high yield, high purity and easy to be industrialized.

Methods and compositions for identifying pesticidal genes are provided. In particular, the methods of the invention comprise systematically designing brush marginal membrane vesicles (BBMVs) from a particular target pest, where the BBMVs are filled with a detectable substance, and then contacting the BBMVs with a candidate pesticidal protein.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

The invention relates to the field of biological medicine, in particular to application of pseudomonas aeruginosa membrane vesicles to preparation of medicine for treating and / or preventing acute pneumonia caused by pseudomonas aeruginosa in subjects. The pseudomonas aeruginosa membrane vesicle provided by the invention can effectively eliminate pseudomonas aeruginosa, eliminate inflammatory response caused by the pseudomonas aeruginosa, relieve the symptom of acute pneumonia caused by the pseudomonas aeruginosa and protect the lung function of a subject.

The present invention provides immunogenic compositions and vaccines comprising isolated gonococcal outer membrane vesicles (OMVs). Said isolated gonococcal OMVs display lipooligosaccharide (LOS) glycan structures comprising an oligosaccharide alpha-chain elongating from Hep I having at least four hexose monosaccharides (4Hex or 5Hex) and wherein said LOS is detoxified. The present invention relates to the use of said immunogenic compositions and vaccines in medicine and, more particularly, the use of said immunogenic compositions and vaccines in immunizing a subject against Neisseria gonorrhoeae infection.

Provided herein are vesicular nanocatalysts decorated on their surface with enzymes, such as for industrial use. More particularly, the nanocatalysts include outer membrane vesicles (OMVs) presenting on their surface carbonic anhydrase or a functional fragment or derivative thereof. Uses, methods of manufacture, and compositions of the nanocatalysts are also disclosed herein.

The disclosure relates to anti-inflammatory, oxygen-scavenging membrane vesicles derived from bacteria with modified or absent lipopolysaccharide. The disclosure further relates to pharmaceutical and nutritional compositions comprising these vesicles, and methods of using the same. Methods include therapeutic treatment of diseases associated with gut oxygenation and inflammation, such as inflammatory bowel disease, as well as non-therapeutic methods for supporting gastrointestinal health, promoting a healthy inflammatory response, and maintaining a balanced gut microbiota.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.

This invention provides bfrA Single gene knockout or bfrA Genes and bfrB Double gene knockout of Neisseria gonorrhoeae and its applications involve the field of biotechnology. Research has found that... bfrA Single gene knockout and bfrA and bfrB Double gene knockout of Neisseria gonorrhoeae resulted in increased formation of vesicles on the outer membrane, disruption of the cell wall and cell membrane, reduced adhesion and invasion abilities, decreased bacterial activity, decreased ATP levels, and weakened ability to infect mice. Therefore, knocking out Neisseria gonorrhoeae... bfrA Gene or bfrA and bfrB The dual-gene assay can be used to prepare products for the production of gonococcal outer membrane vesicles and to construct low-pathogenic gonococcal models.

The invention discloses a preparation method of aqueous-phase phospholipid membrane vesicles in DNA (deoxyribonucleic acid). Comprising the following steps: adding an oil phase A into an outer water phase, centrifuging, and forming a phospholipid monomolecular layer at the interface of the oil phase A and the outer water phase; adding the inner water phase into the oil phase B, and emulsifying to obtain emulsified liquid drops wrapped by single-layer phospholipid; and dripping the emulsified liquid to the upper layer of an oil phase of a phospholipid monomolecular layer, centrifuging, absorbing the upper oil phase, and slightly blowing and beating at the bottom of a water phase to obtain the phospholipid. The method comprises the following steps: dissolving DNA and sucrose in pure water to obtain an inner water phase; dissolving glucose and NaCl in pure water to obtain an outer water phase; the preparation method comprises the following steps: dissolving phospholipid in chloroform to obtain phospholipid mother liquor, adding the phospholipid mother liquor into mineral oil, uniformly mixing and oscillating, and supplementing chloroform to obtain an oil phase A and an oil phase B; according to the method, the solubility of phospholipid in an oil phase is improved, the viscosity of the oil phase is properly improved, sucrose and glucose are added into a water phase to provide a density difference, and an emulsification mode is changed, so that stable preparation of the water-phase phospholipid membrane vesicles in the DNA is realized.

The invention belongs to the technical field of synthetic biology and fermentation engineering, and discloses an engineering bacterium for producing Indigoidine based on membrane vesicle engineering reinforced corynebacterium glutamicum and application of the engineering bacterium. According to the invention, the ncp1 gene of corynebacterium glutamicum is knocked out through a CRISPR-Cas12a gene editing technology, connection between cell walls and cell membranes is relieved, and a chassis strain of high-yield extracellular membrane vesicles (OMVs) is constructed; meanwhile, a recombinant expression vector is introduced, indigo synthetase BpsA is positioned and displayed on membrane vesicles by utilizing PorB anchoring protein, and activating enzyme Sfp is co-expressed. In fermentation production, a staged feeding and IPTG (isopropyl-beta-d-thiogalactoside) and Tween-80 dual induction strategy is adopted to promote thalli to express zymoprotein and release a large number of membrane vesicles at the same time. According to the method, the membrane vesicles are used as an extracellular microreactor, so that the'simultaneous synthesis and secretion 'of the indissolvable indigo is realized, the problems of cytotoxicity and metabolic inhibition caused by intracellular precipitation of the product are effectively solved, and the yield and extraction efficiency of the indigo are remarkably improved.

The present application relates to the technical field of biological pharmacy, in particular to a combined drug for treating colitis and application thereof, wherein the volume ratio of Coptis exosome and Salmonella outer membrane vesicle in the combined drug is 1-2:1-3; the concentration of the Coptis exosome and the Salmonella outer membrane vesicle is 9-11 mg / mL. The present application overcomes the limitation of single treatment strategy by innovatively combining the Coptis exosome and the Salmonella outer membrane vesicle, significantly improves the treatment effect, and avoids the side effects of existing drugs. The present application has lower treatment cost, is safer and has no drug resistance problem, and can provide a more effective, safe and economical treatment method for inflammatory diseases such as colitis.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.